CClinicalTrials.gg
CompletedNCT01851616Updated May 10, 2013

Oral Glucosestimulation After Gastric Bypass Surgery

An interventional study of 25g of glucose in 200ml tap water, given orally (plus 50 mg 13C-sodium acetate) and 10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate) in Obesity, sponsored by University Hospital, Basel, Switzerland. Completed at 1 site in Switzerland. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2013-05-10.

Sponsored by University Hospital, Basel, Switzerland · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The objective of this study is to examine gastric emptying and satiety hormones after oral glucose stimulation in 2 different concentrations in morbidly obese patients after Roux-en-Y-gastric-Bypass.

Read the detailed description

After gastric bypass many patients suffer from early and/or late dumping syndrome as a reaction to carbohydrate rich meals. Gastric emptying after bypass is accelerated and nutrition enters the intestine faster, which leads to osmotically driven fluid shifts from the blood to the lumen. Late dumping occurs 1-3 h after eating, and is caused by hyperinsulinemia and is therefore characterized by symptoms of hypoglycemia like weakness, sweating, and dizziness. Many people have both types. In most studies examining satiety hormones after oral glucose stimulation in non-operated patients, glucose loads of 50-75g are used. For a measurable GLP-1 rise a threshold of 2 kcal/min. at the intestine is needed. After gastric bypass gastric emptying is accelerated and less glucose is necessary to reach this threshold. The "threshold load" and "tolerable load without dumping symptoms" is not yet know.

02

Conditions studied

  • Obesity

Keywords

  • glucose, blood
03

In context

Lead sponsor

University Hospital, Basel, Switzerland is the lead sponsor of 968 studies on the registry; 191 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • 6 weeks post gastric bypass surgery,
  • non-diabetic patient

Exclusion criteria

Exclusion Criteria:

  • smoker,
  • diabetes,
  • gastrointestinal motility disorder,
  • medication influencing gastric emptying
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Active comparator
    Glucose 25g

    25g of glucose in 200ml tap water, given orally (plus 50 mg 13C-sodium acetate)

    Dietary Supplement: 25g of glucose in 200ml tap water, given orally (plus 50 mg 13C-sodium acetate)

  • Active comparator
    Glucose 10g

    10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)

    Dietary Supplement: 10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)

Interventions

  • Dietary supplement25g of glucose in 200ml tap water, given orally (plus 50 mg 13C-sodium acetate)
  • Dietary supplement10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)
06

What researchers measure

Primary outcomes

  1. amount of oral glucose leading to increase in satiety hormones

    Time frame: 240 min.

Secondary outcomes

  1. Amount of oral glucose leading to clinical signs of dumping

    Time frame: 240min.

Other outcomes

  1. Gastric emptying after gastric bypass

    Gastric emptying is measured by means of breath test (use of 50 mg 13C-sodium acetate)

    Time frame: 240min

07

Study locations

1 site
  • University Hospital of Basel
    Basel, CH-4031, Switzerland
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 10, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01851616
Lead sponsor
University Hospital, Basel, Switzerland
Responsible party
Sponsor
First posted
May 10, 2013
Start date
Jan 2013
Primary completion
Mar 2013
Completion
Apr 2013
Last update
May 10, 2013

Study contacts

Christoph Beglinger, Prof.
principal investigator · University of Basel

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion